Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence (MDC)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2013 by Johns Hopkins University
Sponsor:
Information provided by (Responsible Party):
John P. Gearhart, M.D., Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01011777
First received: November 10, 2009
Last updated: July 1, 2013
Last verified: July 2013

November 10, 2009
July 1, 2013
July 2013
June 2015   (final data collection date for primary outcome measure)
The ability to inject the MDC product in a safe and tolerable manner in a clinical setting using a descriptive approach. [ Time Frame: Post op day 1, day 40, monthly afterwards for 36 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01011777 on ClinicalTrials.gov Archive Site
changes in urinary incontinence levels and bladder growth in enrolled participants after undergoing autologous MDC injection using cystograms, urodynamic studies, 24-hour pad weight test, continence score, and maximum day & nighttime dry interval. [ Time Frame: Monthly voiding diary. All other parameters measure at baseline and every 6 months for 36 months. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence
A Phase I Clinical Protocol to Study the Safety and Tolerability of Endoscopic Injection of Autologous Muscle Derived Cells (MDC) in Children With Exstrophy-epispadias Complex Related Urinary Incontinence

The aim of this study is to study safety, tolerability and efficacy of muscle derived cell (MDC) therapy in children with bladder exstrophy epispadias induced urinary incontinence.

Bladder exstrophy patients who have undergone primary bladder closure, but have a bladder capacity too low for bladder neck reconstruction (Group 1), have limited additional surgical options that permits urethral voiding and urine storage within a native bladder. Previous studies have demonstrated a positive correlation between bladder capacity and success of bladder neck reconstruction. Likewise, patients who have undergone bladder neck reconstruction but continue to have urinary incontinence (Group 2) are also faced with limited options. Often, both groups are considered for augmentation cystoplasty with closure of the bladder neck requiring intermittent catheter voiding through a surgically constructed continent catheterizable channel. Such major reconstruction has significant associated short and long-term morbidities. Endoscopic injection of MDCs for the treatment of urinary sphincter insufficiency is a potential alternative therapy for these patients. By increasing the outflow resistance and rhabdosphincter contractility, MDC injection may permit more efficient bladder cycling and bladder expansion in Group 1 patients allowing them to proceed on to bladder neck reconstruction. This same increase in resistance and sphincter contractility may allow Group 2 patients to attain urinary continence and avoid any further reconstructive surgical procedures.

Eligible and consented patients would undergo rectus muscle biopsy and immediately transferred to the Cell Therapy Lab for tissue processing and MDC expansion.The MDC expansion process takes approximately 21 days after which cells are harvest and cryopreserved for future injection.Each vial will be filled with cells at a concentration of approximately 2.0 x 107 cells/ml. At the time of planned MDC injection, enrolled patients will return for cystoscopy under anesthesia. At that time, aliquots of MDCs will be removed from the freezer and be allowed to thaw passively in the 30 minutes preceding the time of planned injection. MDC product will be endoscopically injected using an FDA approved DEFLUX™ needle at the level of the external urethral rhabdosphincter and bladder neck. Patients would be assessed for toxicity and adverse events postoperatively at day 1 and 40 followed by semiannual visits for 36 months. variables measured are:

group 1: Bladder capacity, detrusor leak point pressure, bladder filling pressure, post-void residual urine volume, urodynamics, periurethral electromyographic activity, renal - Bladder Ultrasound, cystoscopy.

Group 2: Detrusor leak point pressure, bladder filling pressure, maximum cystometric capacity, post-void residual urine volume, periurethral electromyographic activity, 24 hour pad / diaper weight assessment, voiding diary including incontinence grade and maximum daytime dry interval, renal - Bladder Ultrasound, cystoscopy

Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Bladder Exstrophy
  • Urinary Incontinence
Drug: MDC
After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
Other Name: Autologous Muscle Derived Cells
Experimental: Autologous Muscle Derived Cells
Surgeon will endoscopically inject previously harvested autologous muscle derived cells (MDC) into the same bladder exstrophy patient's urinary sphincter to improve outflow resistance and rhabdosphincter contractility. We will assess tolerability and induction of continence.
Intervention: Drug: MDC
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
20
June 2017
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Group 1 - Males and females at least 2 years of age with:

    • Classic bladder exstrophy with successful primary, secondary, or delayed primary closure and subsequent epispadias repair.
    • Cystography done with 90 days preceding participant identification and at least 12 months after successful bladder closure demonstrating a bladder capacity less than 60cc.
  2. Group 2 - Males and females greater than 5 years of age with:

    • Classic bladder exstrophy with successful primary, secondary, or delayed primary closure and subsequent epispadias repair.
    • Previous bladder neck reconstruction.
    • At the time of participant identification, urinary incontinence defined as leakage of urine at night or leakage of urine at an interval of less than 3 hours in the daytime persisting at least 2 years after bladder neck reconstruction.
  3. Screening labs obtained less than 30 days prior to MDC injection meeting the following criteria:

    • Urinalysis and urine culture demonstrating either no bacterial growth or growth of an organism that can be treated with an appropriate oral antibiotic for 7 days preoperatively. Participants with a positive urine culture should have the urinalysis and urine culture repeated after completion of antibiotics and prior to MDC injection. A negative urine culture must be demonstrated prior to MDC injection.
    • Serum creatinine in normal range for age (Infant: 0.2-0.4 mg/dl; Child 0.3-0.7 mg/dl; Adolescent 0.5-1.0 mg/dl).
    • Negative Study Donor Virology Panel (Hep B surface antigen, HIV 1 / 2 antibody, Hep B core antibody, RPR, HTLV I / II antibody, Hep C antibody). This panel is only done during the screening process and is not repeated during study follow-up.
  4. Parent or legal guardian who is, in the opinion of the investigator, reliable and willing to make themselves and patient available for the duration of the study and are willing to follow study procedures and unit policies.
  5. Parent or legal guardian able to complete and sign the informed consent document.
  6. Negative pregnancy test for sexual active female teenagers. If able to conceive and sexually active, participants must agree to use barrier contraceptives from the time of study enrollment until 6 months after the last MDC injection. Male participants who are able to conceive and are sexually active must agree to use protection as well from the time of study enrollment until 6 months after the last MDC injection.

Exclusion Criteria:

  1. Urodynamic study demonstrating severe uninhibited bladder contractions.
  2. Severe urethral or bladder neck stricture demonstrated during screening cystoscopy or cystogram
  3. Cystography at the time of screening demonstrating Grade IV vesicoureteral reflux (high-grade reflux with dilation of the renal pelvis and blunting or the fornices) or Grade V vesicoureteral reflux (Grade IV findings plus loss of the papillary impression and ureteral tortuosity).
  4. Any degree of renal scarring at the time of screening as demonstrated by DMSA or MAG3 renal scintigraphy in the presence of any grade of vesicoureteral reflux (VUR)
  5. Renal ultrasound demonstrating Society of Fetal Urology Grade III hydronephrosis (widely split renal pelvis, renal calices uniformly dilated, no parenchymal thinning) or Grade IV hydronephrosis (Grade III dilation plus parenchymal thinning). See Appendix D.
  6. Previous injection of bulking agents at the level of the bladder neck (bovine collagen or DEFLUX™)
  7. Positive urine culture resistant to preoperative oral antibiotic therapy
  8. Need for chronic or pulse steroids or history of other congenital or acquired condition that results in immunocompromise
  9. Previous adverse reaction to anesthesia
Both
2 Years and older
No
Contact: John P Gearhart, MD (410) 955-5358 Jgearhart@jhmi.edu
United States
 
NCT01011777
NA_00026757
Yes
John P. Gearhart, M.D., Johns Hopkins University
Johns Hopkins University
Not Provided
Principal Investigator: John P Gearhart, MD Brady Urological Institute, Department of Pediatric Urology
Johns Hopkins University
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP